225Ac-J591 + 177Lu-PSMA for Prostate Cancer

This trial tests a new combination of radiation treatments for individuals with progressive metastatic castration-resistant prostate cancer. The goal is to determine the highest safe dose of these treatments, which aim to target and destroy prostate cancer cells. Participants must have a diagnosis of prostate cancer that has spread and worsened despite previous treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, providing participants the opportunity to be among the first to receive this new therapy.

The trial protocol does not specify if you need to stop taking your current medications. However, you must continue primary androgen deprivation therapy if applicable, and you cannot start new bisphosphonate or Denosumab therapy during a specific assessment period.

Earlier studies have shown promising safety results for the combination of 225Ac-J591 and 177Lu-PSMA-I&T. Research indicates that 225Ac-J591, which targets prostate cancer cells, was well-tolerated by patients, with no maximum tolerated dose reached, suggesting patients generally handled the doses well without severe side effects.

For the combination of 225Ac-J591 and 177Lu-PSMA-617, safety data is also encouraging. Studies have shown that 225Ac-J591 is well-tolerated, with most side effects being mild and manageable. 177Lu-PSMA-617, a similar treatment, has already demonstrated survival benefits in patients with advanced prostate cancer, with side effects generally mild.

Researchers are excited about these treatments for metastatic castration-resistant prostate cancer because they offer a novel approach by combining targeted radionuclide therapies. Unlike traditional treatments like chemotherapy or hormone therapy, 225Ac-J591 and 177Lu-PSMA-I&T/617 use radioactive particles to precisely target and kill cancer cells while sparing healthy tissue. The 225Ac-J591 targets a protein called PSMA on prostate cancer cells, delivering a potent radioactive payload directly to the tumor. Meanwhile, the 177Lu-PSMA compounds also target PSMA but with a different radioactive isotope, potentially enhancing the overall cancer-killing effect. This dual-targeting mechanism could provide a more effective treatment with fewer side effects than current options.

Research has shown that the combination of 225Ac-J591 and 177Lu-PSMA-I&T, which participants in this trial may receive, holds promise for treating prostate cancer. Studies have found that this combination delivers radiation directly to cancer cells, shrinking tumors and slowing the disease in patients with advanced prostate cancer. Initial findings suggest this method can benefit those who have already tried other treatments. Meanwhile, the combination of 225Ac-J591 and 177Lu-PSMA-617, another treatment option in this trial, also shows potential. Early research indicates it can significantly aid patients by precisely targeting prostate cancer cells. These therapies use radiation attached to molecules that specifically seek out cancer cells, aiming to minimize damage to healthy tissues.²⁴⁶⁷⁸